Mode
Text Size
Log in / Sign up

HIFU ranks highest for fibroid volume reduction and hormonal stability in network meta-analysisHigh intensity focused ultrasound shows promise for uterine fibroids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider HIFU as a high-ranking option for fibroid volume reduction and hormone stability in symptomatic patients.

This network meta-analysis evaluated several interventions including high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), microwave ablation (MWA), and uterine artery embolization (UAE) compared to myomectomy for women with symptomatic uterine fibroids. The analysis included a total of 2622 patients.

For the primary outcome of fibroid volume reduction, HIFU ranked highest with a SUCRA of 96.7%. Specifically, HIFU showed superior results compared to UAE (WMD = 10.31; 95% CI: 3.52-17.10) and RFA (WMD = 3.66; 95% CI: 1.71-5.61). HIFU also ranked highest for recurrence prevention (SUCRA = 70.1%), LH stability (SUCRA = 58.4%), and FSH stability (SUCRA = 68.4%). In contrast, UAE was ranked first for estradiol stability (SUCRA = 77.0%). Regarding safety, MWA (SUCRA = 78.8%) and HIFU (SUCRA = 69.7%) were associated with the lowest incidence of adverse events.

The authors note that the evidence is limited. These findings provide a basis for individualized treatment decisions regarding uterine fibroids, though clinical application should be tempered by the acknowledged lack of extensive data.

How this fits prior evidence

This network meta-analysis addresses gaps in comparing non-surgical interventions for uterine fibroids. It builds upon previous coverage regarding myomectomy as a standard for improving pregnancy chances and identifying predictors like tumor size for recurrence risk. While prior evidence highlighted surgical risks, this analysis provides comparative data on HIFU, RFA, MWA, and UAE for volume reduction and hormonal stability.

Living with uterine fibroids can be physically and emotionally draining. When looking for treatment options, women often weigh the benefits of different procedures against their potential side effects. A large review of 2,622 patients compared several methods, including surgery and non-invasive technologies like high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and microwave ablation (MWA).

The study found that HIFU ranked highest for reducing the size of fibroids. It also performed better than other methods at preventing the fibroids from coming back. Additionally, HIFU showed strong results in keeping hormone levels stable. While uterine artery embolization (UAE) was found to be superior specifically for maintaining estradiol stability, HIFU still emerged as a top performer across many categories.

Safety is a major concern when choosing a treatment. The data showed that microwave ablation and HIFU had the lowest rates of complications among the methods studied. However, it is important to note that the overall evidence is currently limited. Because these findings come from a network meta-analysis rather than a single trial, patients should talk to their doctor to see which option fits their specific needs.

What this means for you:
High-intensity focused ultrasound shows high effectiveness in shrinking fibroids and preventing regrowth.

Common questions

What are the benefits of using HIFU for uterine fibroids?

HIFU ranked highest for reducing the volume of fibroids compared to other methods like radiofrequency ablation and uterine artery embolization. It also performed best at preventing fibroid recurrence and maintaining stable hormone levels, specifically luteinizing hormone and follicle-stimulating hormone.

Is HIFU a safe option for treating fibroids?

The study found that high-intensity focused ultrasound (HIFU) had one of the lowest rates of adverse events among the treatments compared. However, because the overall evidence is limited, you should discuss your specific health risks and safety concerns with your doctor.

How does HIFU compare to other treatments like UAE?

HIFU was found superior to uterine artery embolization (UAE) for shrinking fibroid size and preventing recurrence. However, UAE was ranked first specifically for maintaining estradiol stability. Each treatment has different strengths depending on the specific goal of the treatment.

Study Details

Study typeSystematic review
Sample sizen = 2,622
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Uterine fibroids (UFs) substantially affect the health of women of reproductive age. Minimally invasive and noninvasive therapies have become the main alternatives to traditional surgery; however, evidence on their comparative efficacy remains fragmented. This network meta-analysis compared high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), microwave ablation (MWA), and uterine artery embolization (UAE) with myomectomy (Myo) for symptomatic UFs. METHODS: Eight databases were searched (Jan 2016-Dec 2025) for randomized controlled trials (RCTs). ROB 2.0 and Stata 15.1 were used to analyze fibroid volume, recurrence counts, luteinizing hormone [LH], follicle-stimulating hormone [FSH], estradiol [E], and adverse events using surface under the cumulative ranking curve (SUCRA) values, weighted mean differences (WMDs), and 95% confidence intervals (95% CIs). RESULTS: Thirty-one RCTs (2622 patients) were included. HIFU ranked highest for fibroid volume reduction (SUCRA = 96.7%; vs UAE: WMD = 10.31, 95% CIs: 3.52-17.10; vs RFA: WMD = 3.66, 95% CIs: 1.71-5.61) and recurrence prevention (SUCRA = 70.1%). Fluctuations in ovarian function indicators across therapies were clinically acceptable. HIFU ranked first for stabilizing LH (SUCRA = 58.4%) and FSH (SUCRA = 68.4%), whereas UAE ranked first for E stability (SUCRA = 77.0%). For safety, MWA (SUCRA = 78.8%) and HIFU (SUCRA = 69.7%) had the lowest incidence of adverse events. CONCLUSION: HIFU showed overall efficacy advantages, MWA showed a safety advantage, and UAE may suit specific patient populations. This study provides evidence-based support for individualized treatment decisions for UFs. However, these findings require cautious interpretation due to limited evidence. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD420251273503).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.